Join Johanna Wicks and me in today's Hot Take as we unravel the complicated process of getting treatments added to Australia's PBS, sparked by a recent breakthrough announcement about endometriosis medication.

We explore the pivotal, yet often misunderstood, roles that pharmaceutical companies and the government play in this process and why modern menopause hormone therapy (MHT) hasn't yet made it to the PBS despite public demand.

Delving deeper, we contrast MPA, a synthetic progestin, with body-identical progesterone and critique the Pharmaceutical Benefits Advisory Committee's (PBAC) tendency to group these therapies together. This sheds light on the broader issue of insufficient research funding in women's health.

As we look forward, our anticipation builds around the government's response to the Senate Inquiry report and its potential impacts on women's health policy, especially with an upcoming election.

Will Australian women receive an early Christmas gift from the Government? We hope so!

Jo shares about attending Em Rusciano's impactful "Outgrown" show. And to wrap the year up, have you checked out our creative "Menopause Myths Advent Calendar 2024" on Instagram — a fun, festive initiative aimed at busting menopause myths with a sprinkle of Christmas joy.

Thank you for your continued support and here's to more insightful discussions in the new year!

Links:
Pharmaceutical Benefits Advisory Committee (PBAC)
Em Rusciano
The Holderness Family - Instagram Christmas Reel
2024 Advent Calendar - Instagram

Thank you for listening to my show!

Join the conversation on Instagram